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BACKGROUND: Gold(III) porphyrin 1a is a new class of anticancer drug, which inhibits cell proliferation of wide range of human cancer
cell lines and induces apoptosis in human nasopharyngeal carcinoma cells. However, the underlying signalling mechanism by which
gold(III) porphyrin 1a modifies the intracellular apoptosis pathways in tumour cells has not been explained in detail in neuroblastoma
cells.
METHODS: Cell proliferation and apoptosis were determined by measuring 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) and Annexin V binding, respectively. Western blot assay was used to detect proteins involved in apoptotic and Akt
pathways. In vivo tumour growth was assessed by inoculating tumour cells to nude mice subcutaneously, and gold(III) porphyrin 1a
was administrated intravenously.
RESULTS: This study assessed the antitumour effect and mechanism of gold(III) porphyrin 1a on neuroblastoma in vitro and in vivo.
Gold(III) porphyrin 1a displayed a growth inhibition and induction of apoptosis in neuroblastoma cells effectively in vitro, which was
accompanied with release of cytochrome c and Smac/DIABLO and caspases activation. Further studies indicated that gold(III)
porphyrin 1a inhibited X-linked inhibitor of apoptosis (XIAP). However, we found that gold(III) porphyrin 1a can induce a survival
signal, Akt activation within minutes and could last for at least 24h. To further confirm association between activation of Akt and the
effectiveness of gold(III) porphyrin 1a, neuroblastoma cells were treated with API-2, an Akt-specific inhibitor. API-2 sensitised cells to
gold(III) porphyrin 1a-induced apoptosis and growth inhibition.
CONCLUSION: These results suggested that Akt may be considered as a molecular ‘brake’ that neuroblastoma cells rely on to slow
down gold(III) porphyrin 1a-induced apoptosis and antiproliferation. Gold(III) porphyrin 1a is a mitochondrial apoptotic stimulus but
also activates Akt, suggesting an involvement of Akt in mediating the effectiveness to growth inhibition and apoptosis by gold(III)
porphyrin 1a and that inhibition of Akt can enhance the anticancer activity of gold(III) porphyrin 1a in neuroblastoma.
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Neuroblastoma is one of the most common malignant tumours in
children, and is responsible for about 15% of all paediatric cancer
deaths. (Maris and Matthay, 1999) Spontaneous regressions and
differentiation in vivo are common in infants and in early-stage
tumours, whereas children who are over 1 year of age at clinical
presentation often have metastatic disease that fails to respond to
current therapies, including intensive chemotherapy, irradiation
therapy, and surgery. (Matthay et al, 1999; Weinstein et al, 2003)
The underlying biological mechanism has not been fully eluci-
dated. Despite recent advances in the management of the disease
by conventional chemotherapy, the development of new therapeu-
tic strategies is critically important.
Apoptosis is mediated by two central pathways: the extrinsic (or
death receptor) and the intrinsic (or mitochondrial) pathways
(Danial and Korsmeyer, 2004). The intrinsic pathway is initiated
through either the disruption of the mitochondrial membrane
potential directly or indirectly through upstream effector mole-
cules. This disruption leads to the release of cytochrome c and the
formation of the apoptosome complex of cytochrome c/caspase 9/
Apaf-1 and activation of the caspase cascade leading to apoptosis.
Several endogenous proteins antagonize the intrinsic pathway such
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sas X-linked inhibitor of apoptosis (XIAP). X-linked inhibitor of
apoptosis binds to and inhibits caspase-9, 3, and 7 (Deveraux et al,
1998). The release of Smac/DIABLO from mitochondrial to the
cytosol opposes the inhibition of caspases by XIAP (Du et al,
2000). This relief of inhibition is mediated by binding Smac/
DIABLO to XIAP, displacing the caspases. The role of Smac/
DIABLO emphasizes that although release of cytochrome c is
necessary, it is not sufficient in many situations to bring about cell
death (Potts et al, 2003). Inactivation of the ‘cell death brakes’ by
these other apoptogens is also often necessary for apoptosis to
occur (Crow et al, 2004).
The phosphatidylinositol 30-kinase (PI3K)–Akt signalling path-
way regulates fundamental cellular functions such as transcription,
translation, proliferation, growth, and survival (Osaki et al, 2004).
It has been shown that Akt is capable of interfering with both the
intrinsic (mitochondrial) and extrinsic (receptor mediated)
apoptotic pathways (Nicholson and Anderson, 2002). Inhibiting
Akt signalling in tumour cells led to selective induction of
apoptosis in tumour cells expressing activated Akt. In contrast, a
minimal effect was observed in normal or tumour cells expressing
low levels of active Akt (Jetzt et al, 2003). These studies state the
importance of Akt activation in tumour cell survival. Recent
studies have shown that the activation of Akt also contributes to
both chemotherapeutic resistance and radiation resistance in non-
small cell lung cancer and other carcinoma (Brognard et al, 2001;
Clark et al, 2002). However, the importance of Akt in promoting
therapeutic resistance in neuroblastoma cells has not been
established.
Gold(III) porphyrin 1a is a novel antitumor chemotherapeutic
reagent (Che et al, 2003). Preliminary data showed that gold(III)
porphyrin 1a inhibited cell proliferation of wide range of human
cancer cell lines, including human cervical epithelioid cancer cells,
leukaemia, hepatocellular, and nasopharyngeal carcinoma cells
(Che et al, 2003; Wang et al, 2005) in vitro, suggesting that this
molecule may offer novel approach to cancer therapy. Very recent
data showed that gold(III) porphyrin 1a induced apoptosis in
human nasopharyngeal carcinoma cells through mitochondrial
death pathways related to reactive oxygen species (ROS) (Wang
et al, 2005, 2006). However, the underlying signalling mechanism
by which gold(III) porphyrin 1a modifies the intracellular
apoptosis pathways in tumour cells has not been explained in
detail in neuroblastoma cells. Thus, in this study, we reported that
gold(III) porphyrin 1a induced neuroblastoma cell apoptosis and
growth inhibition both in vitro and in vivo. We showed that
gold(III) porphyrin 1a-induced apoptosis was through the activa-
tion of caspases and mitochondria pathway. Most interestingly,
gold(III) porphyrin 1a lead to the activation of Akt before the onset
of apoptosis, suggesting that early activation of Akt by gold(III)
porphyrin 1a may act as a molecular brake on gold(III) porphyrin
1a-induced apoptosis and thus may serve as new mechanism of
therapeutic resistance. Inhibition of Akt activity might increase
therapeutic efficacy of gold(III) porphyrin 1a in neuroblastoma.
MATERIALS AND METHODS
Reagents
Gold(III) porphyrin 1a was synthesised and purified by a method
described previously (Che et al, 2003). Antibodies for phosphory-
lated Akt (p-Akt), Akt, caspase-3, caspase-9, PARP, and b-actin
were from Cell Signaling (Cell Signaling Technology, Beverly, MA,
USA). Chemiluminescence Western Blot detection reagents were
from Perkin-Elmer (Boston, MA, USA). All other chemicals were
purchased from Sigma (St Louis, MO, USA). Tissue culture plastic
was purchased from Corning (Corning, NY, USA). Cell culture
medium DMEM, fetal bovine serum (FBS) and antibiotics were
from Mediatech Inc. (Herndon, VA, USA).
Cell lines and culture
Neuroblastoma cell lines SK-N-AS and SK-N-SH were obtained
commercially from American Type Culture Collection (ATCC,
Rockville, MD, USA) and cells were cultured with DMEM medium
supplemented with 10% (v/v) heat inactive FBS, 100Uml
 1
penicillin and 100mgml
 1 streptomycin in a humidified 5% CO2
incubator at 371C. The human non-tumorigenic, immortalised
liver cell line MIHA was maintained in Waymouth’s MB 752/1
medium (Gibco BRL, Grand Island, NY, USA) supplemented with
10% FBS, 100Uml
 1 penicillin, 100mgml
 1 streptomycin, 50mM
dexamethasone and 20mUml
 1 insulin (Boehringer Mannheim,
Indianapolis, IN, USA).
Apoptosis assay
Apoptosis was detected by fluorescein-labelled Annexin V staining
using the Annexin V-Fluos staining kit (Roche, Mannheim,
Germany). Cells were treated with gold(III) porphyrin 1a at
different concentrations. Cells were washed with ice-cold phos-
phate-buffered saline (PBS), trypsinised, and labelled with
Annexin V for 15min at room temperature in the dark. The
percentage of FITC-positive cells was analysed by flow cytometry
(FACScaliber, Becton Dicknison, Mountain View, CA, USA). The
data were analysed using CellQuest software (Becton Dicknison).
Proliferation assay
Cells were treated with different concentrations of gold(III)
porphyrin 1a from 0.125 to 1.0mM for 48h. Cell proliferation was
determined by measuring 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide (MTT) reduction following the protocol
(Cell Proliferation kit, BD Biosciences, San Jose, CA, USA), with a
microtiter plate reader (Bio-Rad Model 550, Hercules, CA, USA) at
570nm. Optical density was measured at 570nm. Data were obtained
from three separate experiments. The percentage of cell survival was
determined by comparing the absorbance value of the vehicle
control.
Isolation of cytosolic fractions
The assay was performed according to the method of (Bossy-Wetzel
et al (1998) with minor modifications. Cells were washed in cold
PBS twice and resuspended in mitochondria isolation buffer (20mM
Hepes, pH 7.5, 1.5mM MgCl2,1 0m M KCl, 1mM EDTA, 1mM EGTA,
1m M dithiothreitol, 0.1mM phenylmethylsulfonyl fluoride,
10mgml
 1 leupeptin, aprotinin, and pepstatin containing 250mM
sucrose). Cells were homogenised in an ice-cold tissue grinder with
10 strokes. The homogenate was centrifuged at 900g for 10min.
The resulting supernatant was centrifuged at 13000g for 15min
and pellet was designated as mitochondria. The supernatant was
further centrifuged at 13000g to remove any other particulate
material and supernatant was used as the cytosolic fraction.
Western blot
Cells were washed with PBS, and directly lysed in lysis buffer
(50mM Tris-HCl (pH¼8.0), 1% Triton X-100, 10% glycerol, 1mM
EDTA, 250mM NaCl, 1mM dithiothreitol, 1mM phenylmethylsul-
fonyl fluoride, 2mM sodium vanadate, 100mM sodium fluoride,
10mgml
 1 aprotinin, 10mgml
 1 leupeptin and 10mgml
 1 pepstatin).
Cell lysates were adjusted to equal protein concentrations (Bio-Rad
Protein Assay, Hercules, CA, USA), resuspended in 2  sample
loading buffer containing 4% SDS, 20% glycerol, 120mM Tris and
bromophenol blue, and were boiled for 5min. Protein samples
were subjected to SDS-polyacrylamide gel electrophoresis. Proteins
on the gel were transferred onto nitrocellulose membranes that
were blocked with 5% milk in Tris-buffered saline containing 0.1%
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sTween 20 (TBST) for 1h at room temperature. Afterwards, the
membranes were incubated with the indicated primary antibodies
overnight at 41C. After being washed with TBST, the membranes
were incubated with the appropriate secondary antibody. The
immunoreactive bands were visualised with chemiluminescence.
Tumour growth in nude mice
Six-week-old BALB/c nude mice (Laboratory Animal Unit, The
University of Hong Kong) were injected with neuroblastoma cell
lines SK-N-SH and SK-N-AS subcutaneously with 1 10
6 cell. After
20 days, all of the nude mice developed the tumours. For treatment
group (n¼10), 10mgkg
 1 gold(III) porphyrin 1a dissolved in 10%
ethanol was administrated intravenously on day 21 postinoculation.
Control group (n¼10) received 10% ethanol vehicle. Tumour
growth in each group was monitored everyday by two-dimensional
measurements of individual tumours.
RESULTS
Effects of gold(III) porphyrin 1a on tumour growth in vivo
Mice were inoculated with neuroblastoma cell lines SK-N-AS and
SK-N-SH subcutaneously with 1 10
6 cells. SK-N-SH cell line
possesses multidrug resistance (MDR) phenotype and SK-N-AS
cell line is non-MDR phenotype. (Cinatl et al, 1999) Mice were
administered gold(III) porphyrin 1a (10.0mgkg
 1) every 3 days
intravenously till day 21 postinoculation. Control group received
vehicle alone. Tumour growth in each group was monitored
everyday by two-dimensional measurements of individual
tumours. In control group, tumours in mice inoculated with
SK-N-AS and SK-N-SH grew very progressively. However, treatment
with gold(III) porphyrin 1a resulted in strong and significant
decreases in tumour size both in mice inoculated with SK-N-AS and
SK-N-SH (Figure 1A and B), suggesting that gold(III) porphyrin 1a
not only inhibited non-MDR neuroblastoma growth (SK-N-AS) but
also was effective for MDR phenotype neuroblastoma (SK-N-SH). In
addition, non-MDR cell line SK-N-AS responded significantly better
than the MDR cell line SK-N-SH (Po0.05).
Antiproliferative effects and apoptosis induction of gold
(III) porphyrin 1a
Given these findings in vivo, we further analysed how gold(III)
porphyrin 1a affects tumour growth in vitro. The effects of
gold(III) porphyrin 1a on cell proliferation were assessed in the
human neuroblastoma cell lines SK-N-SH and SK-N-AS. Gold(III)
porphyrin 1a-induced growth inhibitory effects occurred in SK-N-
SH and SK-N-AS with IC50 values 0.2 and 0.4mM, respectively.
However, under the same conditions, the effect of gold(III)
porphyrin 1a on normal live cell (MIHA) was lowered when
compared with SK-N-SH and SK-N-AS (Figure 2A). SK-N-SH cell
line has MDR phenotype and the IC50 values for cisplatin, a
common first-line chemotherapeutic drug in clinical setting,
exceeded 40mM for SK-N-SH and was 10.5mM for SK-N-AS
(Table 1). SK-N-SH is resistant to cisplatin treatment; however,
the sensitivity to gold(III) porphyrin 1a is 100 times more than
cisplatin.
To understand whether gold(III) porphyrin 1a has the effect on
tumour cell apoptosis, cells were treated with gold(III) porphyrin
1a for 12 or 24h and apoptosis was assessed by Annexin V binding
assay. Gold(III) porphyrin 1a induced apoptosis in SK-N-AS and
SK-N-SH but had no effect in normal live cells. Similarly, gold(III)
porphyrin 1a induced more apoptosis at 24h compared with 12h
(Figure 2B and C). Therefore, gold(III) porphyrin 1a-elicited
neuroblastoma cell apoptosis was in time- and dose-dependent
manners.
Gold(III) porphyrin 1a induced release of cytochrome c
and Smac/Diablo
We further explored the mechanism of gold(III) porphyrin 1a-
induced apoptosis of neuroblastoma cells. Apoptotic stimuli can
damage mitochondrial, resulting in cytochrome c and mitochon-
drial protein Smac/Diablo release into the cytosol. Having
previously reported the release of cytochrome c with gold(III)
porphyrin 1a treatment in human nasopharyngeal carcinoma cells
(Wang et al, 2005), we next assessed whether Smac/Diablo was also
released. SK-N-SH and SK-N-AS were treated with gold(III)
porphyrin 1a (0.5mM) for 8h and cytosols were separated. As
showed in Figure 3A, Smac/Diablo was released to cytosol in a
pattern similar to cytochrome c.
Gold(III) porphyrin 1a treatment resulted in
downregulation and cleavage of XIAP
Smac/Diablo is known to exert its proapoptotic effect by inhibition
of XIAP. X-linked inhibitor of apoptosis is a member of
intracellular antiapoptotic proteins that confers protection form
death-inducing stimuli by directly blocking the activation of
caspases (Deveraux et al, 1999). To determine the effect of XIAP in
gold(III) porphyrin 1a-induced apoptotic execution, cells were
treated with gold(III) porphyrin 1a (0.5mM) for different periods of
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Figure 1 Antitumor effect of gold(III) porphyrin 1a in BALB/c-nude mice. Mice were inoculated with SK-N-SH (A) and SK-N-AS (B) subcutaneously with
1 10
6 cells. Tumours developed 20 days after injection and mice were administered gold(III) porphyrin 1a every 3 days intravenously until day 21
postinoculation. Control group received vehicle alone (10% ethanol). The size of tumours in mice was monitored everyday. Results are expressed as the
mean (n¼10 per group, *Po0.05).
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stime. Expression of full-length XIAP (53kDa) in both SK-N-SH
and SK-N-AS was markedly inhibited by gold(III) porphyrin 1a at
time 24h (Figure 3B). The data also showed that the time of Smac/
Diablo release preceded that of XIAP cleavage (Figure 3A and B).
Effect of gold(III) porphyrin 1a on the activation of
caspases
Activation of caspases during apoptosis results in the cleavage and
activation/inactivation of a range of critical cellular substrates,
including the DNA repair enzyme PARP. To determine which
caspases were involved in gold(III) porphyrin 1a-induced apop-
tosis, the expressions of activated caspases were detected by
western blotting. As shown in Figure 3C–E, in control cells,
caspase-9 and -3 and PARP were all present as uncleaved forms.
After the treatment with gold(III) porphyrin 1a for 24h, the
cleavage of caspases and PARP to catalytically active fragments
was clearly detected, suggesting the activation of these caspases.
Gold(III) porphyrin 1a induced phosphorylation of Akt
As Akt activation has been implicated in the promotion of tumour
cell proliferation and some antitumour drugs can inhibit tumour
growth by inactivating Akt, we next examined whether gold(III)
porphyrin 1a could affect Akt. SK-N-SH and SK-N-AS cells were
treated with gold(III) porphyrin 1a (0.5mM) for different periods of
time. Interestingly, we found that Akt activation was not inhibited
by gold(III) porphyrin 1a. By contrast, gold(III) porphyrin 1a
treatment resulted in Akt activation by phosphorylation of Akt at
Ser473 beginning by 30min in both neuroblastoma cells SK-N-AS
and SK-N-SH (Figure 4), suggesting an early induction of Akt
before the onset of apoptosis. Furthermore, the activation of Akt
can last for at least 24h.
Effect of inhibition of Akt activity on the sensitivity of cells
to gold(III) porphyrin 1a treatment
Because activation of Akt can protect cells from apoptosis and our
data showed gold(III) porphyrin 1a-induced early activation of
Akt, we therefore reasoned that whether inhibition of Akt
activation might sensitise cells to gold(III) porphyrin-induced
apoptosis. Akt/protein kinase B signalling inhibitor (API-2), a
cell-permeable tricyclic nucleoside, selectively inhibited cellular
phosphorylation of Akt but not activation of PI3K, PDK1, PKC,
PKA, ERK1/2, or c-Jun NH2-terminal kinase (Yang et al, 2004).
Neuroblastoma cells SK-N-AS and SK-N-SH were pretreated with
or without API-2 (1.0mM) for 2h and then treated with gold(III)
porphyrin 1a for 24h. API-2 at 1.0mM can inhibit Akt activation
(data not shown) but did not affect cell growth and apoptosis
(Figure 5). Treatment with API-2 enhanced tumour cell sensitivity
to gold(III) porphyrin 1a-induced growth inhibition in a dose-
dependent manner (Figure 5A). The IC50 values for gold(III)
porphyrin 1a in SK-N-AS and SK-N-SH treated with API-2 were 0.1
and 0.2mM compared with 0.2 and 0.4mM in cells treated with
gold(III) porphyrin 1a alone (Figure 5A). To assess how inhibition
of Akt activation would affect gold(III) porphyrin 1a-induced
apoptosis, cells were treated with gold(III) porphyrin alone or the
combinations of API-2 (1.0mM) and gold(III) porphyrin 1a for
24h. When treatment was combined with API-2, gold(III)
porphyrin 1a resulted in dose-dependent apoptosis induction that
was greater than that observed at the same concentration of
gold(III) porphyrin 1a without API-2 treatment (Figure 5B), which
is consistent with the antiproliferative assay results.
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Figure 2 Proliferative and apoptotic effects of gold(III) porphyrin 1a on
neuroblastoma cells. (A) SK-N-SH, SK-N-AS and MIHA (normal liver cell
line) cells were cultured with gold(III) porphyrin 1a for 48h in 96-well plate.
The proliferation was evaluated by MTT assay. Each treatment group
contained eight replicates. Data expressed as mean±s.d. and similar results
were obtained from independent experiments. (B and C) SK-N-SH, SK-N-
AS, and MIHA cells were cultured with gold(III) porphyrin 1a for 12h
(B) and 24h (C). Apoptosis of gold(III) porphyrin 1a on neuroblastoma
cells was evaluated by Annexin V staining. Data expressed as mean±s.d.
and similar results were obtained from independent experiments.
Table 1 Cytotoxicity (IC50) of Gold(III) porphyrin on neuroblastoma cell
lines
IC50 (lM)
Cell lines Gold(III) porphyrin 1a Cisplatin
SK-N-AS (non-MDR phenotype) 0.2 10.5
SK-N-SH (MDR phenotype) 0.4 440.0
Normal liver cells 1.75 38.5
MDR¼multidrug resistance.
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sDISCUSSION
Gold(III) porphyrin 1a, a chemically synthetic compound with a
simple chemical structure, is a novel class of antitumour drug (Che
et al, 2003). It displayed antiproliferative activity in several types of
human cancer cells (Wang et al, 2005, 2006; Lum et al, 2006).
However, the precise target and mechanism of action of gold(III)
porphyrin 1a on tumour cells remain largely unknown.
In this study, we showed that gold(III) porphyrin 1a induced
apoptosis and growth inhibition in neuroblastoma cells, including
MDR cells in vivo and in vitro. Importantly, there is no cytotoxicity
in normal liver cells and peripheral blood mononuclear cells (data
not shown). This in vitro result was confirmed by that of the
in vivo study. Gold(III) porphyrin 1a treatment was active against
neuroblastoma xenografts and significantly inhibited tumour
growth. These data show that the antitumor activity exerted by
gold(III) porphyrin 1a is effective, in vivo, in treating cancer.
Numerous stimuli and stresses are able to stimulate the release
of apoptogenic factors from the mitochondrial intermembrane
space, leading to the programmed demise of the cell. To
understand the mechanism by which gold(III) porphyrin 1a
induces apoptosis of tumour cells, we have examined the changes
in the expression and localisation of several apoptosis-related
proteins in neuroblastoma cells exposed to gold(III) porphyrin 1a.
The western blot analysis revealed that gold(III) porphyrin 1a
induced the release of cytochrome c and Smac/Diablo, activation of
caspase-9 and -3, and PARP cleavage, indicating that gold(III)
porphyrin 1a-induced apoptosis might be primarily mediated by
the mitochondrial (intrinsic) apoptosis pathway. We further
explored the expression of XIAP in neuroblastoma cell lines. We
found that SK-N-SH and SK-N-AS expressed high levels of XIAP.
These findings correlated with previous studies showing that IAPs
are highly expressed in many tumours and contribute to the
resistance of cancers to apoptosis (Deveraux et al, 1998; Salvesen
and Duckett, 2002; Kamsteeg et al, 2003). Treatment of the
neuroblastoma cells with gold(III) porphyrin 1a inhibited the
expression of XIAP. It has been shown that the cleavage of XIAP
may be one of the mechanisms by which cell death programs
circumvent the antiapoptotic barrier posed by XIAP (Deveraux
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Figure 3 Characterisation of gold(III) porphyrin 1a-mediated apoptosis in neuroblastoma cells. (A) Smac and cytochrome c release in neuroblastoma cells
treated with gold(III) porphyrin 1a. SK-N-SH and SK-N-AS were treated with gold(III) porphyrin 1a (0.5mM) for 8h and Smac and cytochrome c in cytosol
were detected by western blot analysis. SK-N-SH and SK-N-AS cells were also treated with gold (III) porphyrin 1a (0.5mM) for different periods of time.
Western blotting was applied to analyse the expression of full-length XIAP (53kDa) (B), full-length (47kDa) and cleaved caspase-9 (37/35kDa) (C), full-
length (35kDa) and cleaved caspase-3 (19/17kDa) (D), and full-length (116kDa) and cleaved PARP (89kDa) (E).
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Figure 4 Effect of gold(III) porphyrin 1a on induction of Akt activity.
SK-N-SH and SK-N-AS cells were treated with gold(III) porphyrin 1a
(0.5mM) for different periods of time. Akt phosphorylation and total Akt
expression was analysed by western blotting.
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set al, 1999). This may explain our findings of caspase-9 activation
after gold(III) porphyrin 1a treatment.
Recent study showed that the majority of cytochrome c release
was abolished in the Smac-KO cells, suggesting that Smac plays an
important role in promoting cytochrome c release and full
execution of NSAID-induced apoptosis (Bank et al, 2008). Studies
by other groups also showed that the release of different
mitochondrial apoptogenic proteins is coordinated and occurs
through different time courses (Munoz-Pinedo et al, 2006). Our
data showed for the first time that gold(III) porphyrin 1a not only
enhanced cytochrome c release but also promoted Smac release.
Smac release may be critical for its ability to promote caspase
activation and cytochrome c release during gold(III) porphyrin 1a-
induced apoptosis. The release of Smac and cytochrome c may
have synergetic role on apoptosis by the activation of caspase-9
and inhibition of XIAP. Further study is needed to explore the
requirement of Smac for full execution of gold(III) porphyrin 1a-
induced apoptosis in neuroblastoma cells.
It is well documented that Akt can promote cellular survival. Akt
is activated in response to many different growth factors (Datta
et al, 1999). Previous studies also showed that Akt plays important
roles in cell survival when cells are treated with different apoptotic
stimuli such as growth factor withdrawal, UV irradiation, and
etoposide (Widmann et al, 1998). Akt protects cells from apoptosis
by phosphorylating and inactivating several key apoptotic
molecules: Bad, procaspase-9, and FKHR1 (Pommier et al, 2004).
Our results showed for the first time that gold(III) porphyrin 1a
not only enhanced neuroblastoma apoptosis but also activated Akt,
the survival signal. Inhibition of Akt activation sensitised
neuroblastoma cells to the effects of antiproliferation and
apoptosis by gold(III) porphyrin 1a. The antiproliferation and
apoptosis induced by gold(III) porphyrin 1a on cells could be
enhanced by the inhibition of Akt activation pharmacologically
with specific Akt inhibitor, suggesting that Akt activation might
play a role in the protection against the effects of apoptosis and
growth inhibition of gold(III) porphyrin 1a in neuroblastoma. To
our knowledge, these studies are the first to show that Akt is a
survival factor for neuroblastoma cells under conditions of with
administration of gold(III) porphyrin 1a, which are similar to the
previous studies that showed that the Akt activity was induced by
chemotherapy, doxorubicin, trastuzumab, or tamoxifen (Clark
et al, 2002). This phenomenon was also observed by Tang et al
(2001), who showed that Akt was activated in response to
apoptotic stimuli: staurosporine and etoposide.
What is the mechanistic connection between gold(III) porphyrin
1a and Akt induction? It has been shown that gold(III) porphyrin
1a can generate ROS (Wang et al, 2005) which may contribute to
Akt activation in a similar way to hydrogen peroxide as some
apoptotic stimuli such as doxorubicin-generated ROS and UV B
irradiation-induced DNA damage can activate Akt (Ushio-Fukai
et al, 1999; Van der Kaay et al, 1999; Wang et al, 2000). However,
the activation of Akt by hydrogen peroxide occurred within
minutes and was transient, whereas our study showed that
gold(III) porphyrin 1a-induced activation of Akt can last for at
least 24h and was not transient. This result suggests that other
mechanisms may be involved to alter Akt levels in neuroblastoma
cells in response to gold(III) porphyrin 1a. Other reports have
showed that Akt can also be activated by other factors such as
heat-shock proteins (Konishi et al, 1997; Rane et al, 2003; Solit
et al, 2003) or by other cellular stress such as hypoxia (Alvarez-
Tejado et al, 2001). Therefore, further studies are needed to
identify the mechanisms of Akt activation induced by gold(III)
porphyrin 1a.
Akt activation contributes to chemotherapeutic resistance and
radiation resistance in breast, lung, prostate and ovarian
carcinomas, leukaemia and melanoma (Krasilnikov et al, 1999;
Wellbrock et al, 1999; Brognard et al, 2001; Chen et al, 2001;
Stassi et al, 2005). It has been reported that a growth/survival
factor-stimulated mechanism leading to chemoresistance in
neuroblastoma is mediated by the PI3K/Akt signalling pathway
(Li and Thiele, 2007). These findings raise the possibility of a
new therapeutic approach in neuroblastoma that would target
Akt to enhance the efficacy of chemotherapeutics. Combination
regimens of gold(III) porphyrin 1a with an Akt inhibitor might
have even great efficacy in MDR neuroblastoma cells. Several
small-molecule inhibitors of the PI3K/Akt pathway are in active
preclinical development (Powis et al, 2006). Specific Akt
inhibitors such as API-2, a cell-permeable tricyclic nucleoside
that selectively inhibits cellular pAkt by targeting the Akt
effector molecule, do so without inhibition of activation of the
upstream PI3K and PDK1 or downstream molecules (Yang et al,
2004). Although neuroblastoma SK-N-SH cell line assessed was
less sensitive to gold(III) porphyrin 1a compared with SK-N-AS
in vitro and in vivo, inhibition of Akt activation enhanced
gold(III) porphyrin 1a response in these cells. Thus, p-Akt and
its upstream activating pathway, PI3K, may have a critical role in
%
 
P
r
o
l
i
f
e
r
a
t
i
o
n
%
 
P
r
o
l
i
f
e
r
a
t
i
o
n
SK-N-AS
Gold(III) porphyrin 1a (M)
0
0 0.125 0.25 0.5 1
0
0
0.125 0.25
0.25
0.5
0.5
1
1 0 0.25 0.5 1
20
40
60
80
100
120
0
20
40
60
80
100
120
Control
API-2 
Control
API-2 
SK-N-SH
% Apoptosis
SK-N-SH                   SK-N-AS
0
10
20
30
40
50
60
70
80
90
Control
API-2
Gold(III) porphyrin 1a (M)
A
B
Figure 5 Inhibition of Akt activity sensitises cells to gold(III) porphyrin
1a-induced proliferative inhibition and apoptosis. (A) SK-N-SH and SK-N-
AS cells were pretreated with or without API-2 (1mM) for 2h and then
cultured with gold(III) porphyrin 1a for 48h. Proliferation was assessed by
MTT assay. Each treatment group contained eight replicates. Data were
expressed as mean±s.d.; similar results were obtained from repeated
experiments. (B) SK-N-SH and SK-N-AS cells were pretreated with or
without API-2 (1mM) for 2h and then cultured with gold(III) porphyrin 1a
for 24h. Apoptosis was assessed by Annexin V binding assay. Data were
expressed as mean±s.d.; similar results were obtained from duplicate
experiments.
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sconferring resistance to apoptosis induction by gold(III)
porphyrin 1a. As Akt is vital for endothelial cell function and
vascular integrity, its inhibition might also potentiate the
antitumour effects of gold(III) porphyrin 1a (Somanath et al,
2006).
Taken together, our data emphasise that gold(III) porphyrin 1a
is a mitochondrial apoptotic stimulus and reveal the potential
importance of Akt as a therapeutic target in neuroblastoma. Akt
may be considered as a molecular ‘brake’ that neuroblastoma cells
rely on to slow down gold(III) porphyrin 1a-induced apoptosis and
antiproliferation. It is possible that the activation of Akt inhibits
the desired antitumor effects of gold(III) porphyrin 1a, particularly
in the cells in which Akt is largely amplified. Inhibition of Akt
activity by specific inhibitor can remove the apoptotic ‘brake’ and
sensitise the neuroblastoma cells to gold(III) porphyrin 1a
treatment.
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